Now showing items 1-2 of 2

    • A phase I study of ABT-510 plus bevacizumab in advanced solid tumors. 

      Bendell, JC; Blobe, GC; Cushman, SM; Dellinger, Andrew; Gockerman, J; Hurwitz, HI; Li, H; ... (13 authors) (Cancer Med, 2013-06)
      Targeting multiple regulators of tumor angiogenesis have the potential to improve treatment efficacy. Bevacizumab is a monoclonal antibody directed against vascular endothelial growth factor and ABT-510 is a synthetic analog ...
    • Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironment. 

      Augustine, C; Beasley, G; Blobe, GC; Campbell, OM; Evans, Kathy; George, A; Gimpel, P; ... (20 authors) (J Clin Invest, 2013-09)
      Cancers subvert the host immune system to facilitate disease progression. These evolved immunosuppressive mechanisms are also implicated in circumventing immunotherapeutic strategies. Emerging data indicate that ...